.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR24_LamivudineTenofovirDisoproxilAnd.LamivudineTenofovirDisoproxilAnd .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR24_LamivudineTenofovirDisoproxilAnd.LamivudineTenofovirDisoproxilAnd| name: | LamivudineTenofovirDisoproxilAndDoravirine |
| ATC code: | J05AR24 |
| route: | oral |
| n-compartments | 1 |
Fixed-dose combination of antiretrovirals used for the treatment of HIV-1 infection in adults and adolescents. Each drug acts at different steps in the viral lifecycle: lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI), and doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). The combination is approved and used as a complete regimen for HIV management.
Estimated mean pharmacokinetic parameters for healthy adults at steady state following single oral administration of fixed-dose combination tablet containing lamivudine 300mg, tenofovir disoproxil 300mg, and doravirine 100mg.